• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Allergan

Allergan

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Allergan , Valeant, Pershing Square settle lawsuit

    Allergan , Valeant, Pershing Square settle lawsuit

  2. Valeant, Allergan , and Pershing Square Have Agreed to Drop Lawsuit in Allergan v. Valeant Pharmaceuticals International

    Valeant, Allergan , and Pershing Square Have Agreed to Drop Lawsuit in Allergan v. Valeant Pharmaceuticals International

  3. Research and Markets: Thrombus Partnering Deals and Agreements Analysis 2010-2015

    Research and Markets: Thrombus Partnering Deals and Agreements Analysis 2010-2015

  4. Meet Pharma's Newest Movers and Shakers, Driving M&A

    Meet Pharma's Newest Movers and Shakers, Driving M&A

  5. Meet Pharma's Newest Movers and Shakers, Driving M&A

    Meet Pharma's Newest Movers and Shakers, Driving M&A

  6. Teva Offers to Buy Mylan for $40 Billion -- 5th Update

    Teva Offers to Buy Mylan for $40 Billion -- 5th Update

  7. Icon Bioscience Reports Successful Outcomes of Phase 3 Study of IBI-10090, a Novel Sustained Release Drug Being Developed to Treat Inflammation Associated with Cataract Surgery

    Icon Bioscience Reports Successful Outcomes of Phase 3 Study of IBI-10090, a Novel Sustained Release Drug Being Developed to Treat Inflammation Associated with Cataract Surgery

  8. Research and Markets: Top 50 Big Biotech Partnering and M&A Deal Trends Report 2015

    Research and Markets: Top 50 Big Biotech Partnering and M&A Deal Trends Report 2015

  9. A Wide-Moat Opportunity in Health Care

    Actavis' transformation to a wide-moat company following its deal with Allergan represents a good buying opportunity for long-term investors.

  10. Actavis Seeking FDA Approval to Market Generic Version of Gilead Drug

    Actavis Seeking FDA Approval to Market Generic Version of Gilead Drug

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.